Aldeyra Therapeutics Files 8-K
Ticker: ALDX · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1341235
| Field | Detail |
|---|---|
| Company | Aldeyra Therapeutics, INC. (ALDX) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Aldeyra Therapeutics filed an 8-K on June 17, 2025, mostly routine stuff.
AI Summary
On June 17, 2025, Aldeyra Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided excerpt. The company is incorporated in Delaware and headquartered in Lexington, MA.
Why It Matters
This 8-K filing indicates routine corporate reporting by Aldeyra Therapeutics, Inc., providing updates on their regulatory filings and financial disclosures.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without disclosure of significant new risks or material adverse events.
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Registrant
- June 17, 2025 (date) — Date of earliest event reported
- Lexington, MA (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of June 17, 2025.
What is Aldeyra Therapeutics, Inc.'s principal executive office address?
Aldeyra Therapeutics, Inc.'s principal executive offices are located at 131 Hartwell Avenue, Suite 320, Lexington, MA 02421.
In which state is Aldeyra Therapeutics, Inc. incorporated?
Aldeyra Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Aldeyra Therapeutics, Inc.?
The Commission File Number for Aldeyra Therapeutics, Inc. is 001-36332.
What was the former name of Aldeyra Therapeutics, Inc.?
The filing mentions former company names 'Aldexa Therapeutics, Inc.' and 'Neuron Systems Inc' with dates of name changes in 2013 and 2005 respectively.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Aldeyra Therapeutics, Inc. (ALDX).